MedSchool: Ace Your OSCEsThe Medical Company
GET - On the App Store
Drug Guide


    IV infusion
  • Mechanism of Action
  • A monoclonal antibody directed against PD-L1, an inhibitory molecule expressed on certain tumour cells.
  • PD-L1 and PD-L2 are ligands that bind to PD-1 receptors on activated lymphocytes and inhibit T cell receptor signalling, downregulating immune responses and promoting tolerance.
  • Binding of anti-PD-L1 monoclonal antibodies leaves the ligand unable to bind to PD-1, and therefore stimulates an ongoing immune response.
  • PD-L2 is not inhibited, allowing PD-1 / PD-L2 mediated inhibitory signals to continue.

Clinical Use

  • Indications
  • Locally advanced non-small cell lung cancer (NSCLC) without progression post chemoradiotherapy
  • Locally advanced or metastatic urothelial carcinoma with progression post platnium-based chemotherapy
  • Adverse Effects
  • Endocrinopathies - thyroiditis, adrenalitis, hypophysitis, diabetes mellitus
  • Pulmonary toxicity - pneumonitis
  • Hepatotoxicity - LFT derangement, hepatitis
  • GI toxicity - colitis
  • Rheumatological - flares of previous disease
  • Skin - rash, pruritis
  • Fatigue
  • Anorexia
  • Headache
  • Dizziness
  • Nausea / vomiting / diarrhoea
  • Thrombocytopaenia
Want more info like this?
  • Your electronic clinical medicine handbook
  • Guides to help pass your exams
  • Tools every medical student needs
  • Quick diagrams to have the answers, fast
  • Quizzes to test your knowledge
Sign Up Now

Snapshot: Initialising...